A study reported ipamorelin's systemic plasma clearance (how quickly it leaves the blood) was 5-fold lower than GHRP-6's.

A study reported ipamorelin's systemic plasma clearance (how quickly it leaves the blood) was 5-fold lower than GHRP-6's. This result does not prove that ipamorelin binds only one receptor or is safe in clinical use.

A growth hormone secretagogue is a compound that prompts the release of GH. In this setting, selectivity describes how narrowly a compound affects measured hormone outputs.
That is different from receptor selectivity. Receptor selectivity asks which cell receptors a compound binds and activates. A narrow GH response does not, by itself, prove that a compound acts on only one receptor.
GHRP means growth hormone-releasing peptide. GHRP-2, GHRP-6, and hexarelin are synthetic peptides that act at GHS-R1a, like ipamorelin.

The compounds differ in structure and in the hormone responses reported across studies. A result from one GHRP cannot stand in for results from every other GHRP.
Its plasma clearance was 5-fold lower than GHRP-6's in the study.
Plasma clearance means how quickly a compound leaves the blood. Clearance and half-life are related, but they are not the same measure; a clearance result alone does not show how long a hormone response lasts.
GH is the main outcome, but it does not give a full picture of selectivity. A study can also measure adrenocorticotropic hormone (ACTH), a pituitary signal that prompts cortisol release from the adrenal glands.
Cortisol is an adrenal hormone. Prolactin is another pituitary hormone, while aldosterone is an adrenal hormone involved in salt balance. Measuring these signals can help show whether a test compound changes more than GH.
A missing change in one study is not proof that a change can never occur. The result applies to the model, test amount, timing, and assay used in that study.
A head-to-head comparison is most useful when it tests compounds under matched conditions. The model, test amount, timing, route, and hormone assays should be clear.

Timing matters because hormone levels can shift for a short period. A single sample may miss a brief rise or fall, while samples taken across a planned time window can show more of the response.
Assay limits matter too. A study may report no meaningful change when the signal is small or the test cannot measure it well. Good reports state which hormones were checked and how the tests measured them.
Cell assays, animal tests, and human studies answer different questions. Cell assays can show whether a compound activates a receptor or changes cell signals. Animal tests show broader body responses, while human studies test responses in people under a defined research plan.
Those types of evidence are not interchangeable. Results in a cell or animal model do not establish the same response in people, and a narrow hormone profile alone does not establish safety or suitability for clinical use.
GHRH means growth hormone-releasing hormone. It activates a different receptor from GHS-R1a, though both pathways can lead to GH release from pituitary cells.
That pathway differs from ipamorelin's ghrelin-receptor route. The two approaches may share a GH outcome, but they do not use the same receptor as their first step.
Tesamorelin is another synthetic GHRH analog. Comparing it with ipamorelin therefore tests two distinct receptor pathways, rather than two versions of the same GHRP mechanism.
Hormone-response selectivity is a biological finding. It does not show whether a research peptide sample has the right identity or purity.

High-performance liquid chromatography (HPLC) separates the parts of a sample and can help assess purity. Mass spectrometry can help confirm molecular identity. Neither method, on its own, shows how a compound changes hormone levels in a cell, animal, or human study.
A certificate of analysis reading overview concerns material records, while a laboratory testing page concerns sample checks. These records address a different question from GH-release selectivity.
Sample condition can also affect a lab result. Information on cold-chain handling in transit relates to material handling, not the receptor pathway or hormone response.
Ipamorelin selectivity compared with older GH secretagogues is best read as a difference in measured hormone output in specific tests. The reported clearance difference is specific to ipamorelin and GHRP-6; it does not establish a wider hormone-response pattern.
The result does not prove exclusive receptor binding, predict every model, or establish clinical safety. Strong comparisons name the model, match test conditions, and report each hormone endpoint.